Parabilis Medicines, Inc., formerly known as FOG Pharmaceuticals, is a clinical-stage biopharmaceutical company focused on discovering and developing transformative medicines for cancer and other severe diseases. The company's proprietary discovery platform centers on Helicons, a novel therapeutic modality consisting of stabilized alpha-helical peptides. These cell-penetrating mini-proteins are engineered to combine the targeting precision of monoclonal antibodies with the intracellular reach of small molecules, allowing them to bind and modulate flat protein surfaces that were previously considered undruggable. Parabilis's lead product candidate, zolucatetide (formerly FOG-001), is a first-in-class direct inhibitor of the interaction between β-catenin and T-cell factor (TCF) transcription factors. It is currently advancing into late-stage clinical trials for desmoid tumors, as well as being evaluated for colorectal cancer, hepatocellular carcinoma, and other solid tumors driven by Wnt/β-catenin pathway mutations. In addition to zolucatetide, the company is advancing a pipeline of investigational protein degraders, including ERG and allosteric AR degraders for prostate cancer. As a pre-revenue, clinical-stage entity, Parabilis relies on equity financing and strategic partnerships, such as its collaboration with Regeneron Pharmaceuticals, to fund its research and development operations.
